{"ticker": {"uuid": "8ad461a6-4145-4c55-a917-90beabf29233", "symbol": "DMAC", "name": "DiaMedica Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/diamedica-announces-inducement-grants-under-203000631.html", "source_name": "Business Wire", "published_at": "2026-07-17T20:30:00+00:00", "published_display": "17 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New DiaMedica hire gets 160,000 stock options at $7.64", "summary": "DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it granted options to a newly hired non-executive employee to purchase 160,000 shares of common stock. The stock options, with an exercise price of $7.64 per share, were a material inducement for their employment, complyin", "url": "https://www.stocktitan.net/news/DMAC/dia-medica-announces-inducement-grants-under-nasdaq-listing-rule-atn7kk24o63i.html", "source_name": "Stock Titan", "published_at": "2026-07-17T20:10:45", "published_display": "17 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "(DMAC) Risk Channels and Responsive Allocation", "summary": "Diamedica Therapeutics Inc. (NASDAQ: DMAC) is showing conflicting sentiment across horizons, suggesting choppy conditions. The article highlights an exceptional 79.0:1 risk-reward setup targeting a 21.9% gain versus 0.3% risk. AI models have generated three distinct trading strat", "url": "https://news.stocktradersdaily.com/news_release/10/DMAC_Risk_Channels_and_Responsive_Allocation_071526072801_1784114881.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T07:12:23", "published_display": "15 Jul 2026 07:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "DiaMedica Therapeutics (DMAC) Short Interest & Short Float | Updated Jul 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE02NUdaa2lVbm5ncWFKQnZlLUFfSXpCdkI4M3JCZWZ0TjVjdDYwMUtFQnR3bVZwNmlPNHVEM05Qa1JJbXRCaVNpczZFWFN0U0tpX3MwV2o5cmdncjBnNHUxbEhFdU9lSEd0OC1tRDZB?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of DiaMedica Therapeutics Inc. \u2013 NASDAQ:DMAC", "summary": "The article discusses the enterprise value to revenue forward for DiaMedica Therapeutics Inc. (NASDAQ: DMAC). It highlights financial data available on TradingView, covering various aspects of the company's financial performance.", "url": "https://www.tradingview.com/symbols/NASDAQ-DMAC/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T16:12:23", "published_display": "08 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMAC PE Ratio & Valuation, Is DMAC Overvalued", "summary": "DiaMedica Therapeutics Inc (DMAC) is currently in the \"Fair zone\" according to its forward PS ratio, which is 0.00 compared to a five-year average of -4.69. The company's current Price-to-Book (P/B) ratio of 9.14 is significantly higher than its 3-year and 5-year averages, and it", "url": "https://intellectia.ai/en/stock/DMAC/valuation", "source_name": "Intellectia AI", "published_at": "2026-07-08T02:39:32", "published_display": "08 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of DiaMedica Therapeutics Inc. \u2013 NASDAQ:DMAC", "summary": "This article provides the enterprise value to EBITDA forward for DiaMedica Therapeutics Inc. (NASDAQ:DMAC). It presents financial data and company overview information sourced from TradingView, FactSet, and other financial data providers.", "url": "https://www.tradingview.com/symbols/NASDAQ-DMAC/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T03:47:28", "published_display": "07 Jul 2026 03:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics | 10-Q: Q1 2026 Earnings Report", "summary": "This document is the official 10-Q filing for DiaMedica Therapeutics, detailing their earnings report for the first quarter of 2026. As a regulatory filing, it provides a comprehensive overview of the company's financial performance and operational activities during that period.", "url": "https://www.moomoo.com/news/notice/307236683/diamedica-therapeutics-10-q-q1-2026-earnings-report", "source_name": "Moomoo", "published_at": "2026-07-07T03:39:26", "published_display": "07 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of DiaMedica Therapeutics Inc. \u2013 NASDAQ:DMAC", "summary": "This article section displays the \"Price to sales forward\" metric for DiaMedica Therapeutics Inc. (NASDAQ: DMAC). It indicates that the market was closed at the time of viewing and no trades were recorded for this specific financial data point.", "url": "https://www.tradingview.com/symbols/NASDAQ-DMAC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T22:40:31", "published_display": "06 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Inc. Actuals & Estimates (NASDAQ:DMAC)", "summary": "This article provides an overview of DiaMedica Therapeutics Inc. (NASDAQ: DMAC) stock performance, financial estimates, and analyst forecasts. It details the current stock price, historical highs and lows, market capitalization, and upcoming earnings report. The piece also includ", "url": "https://www.tradingview.com/symbols/NASDAQ-DMAC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:46", "published_display": "26 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMAC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for DiaMedica Therapeutics Inc. (DMAC), detailing analyst opinions, historical price performance, and key financial metrics. It highlights that analysts have a max price estimate of $25.00 and a min estimate of $11.00 for DMAC, wit", "url": "https://www.tradingview.com/symbols/NASDAQ-DMAC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T21:09:16", "published_display": "25 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) Short Interest & Short Float | Updated Jun 2026", "summary": "This article provides an update on DiaMedica Therapeutics (DMAC) short interest and short float as of June 15, 2026. DMAC had 4.86 million shares sold short, representing 9.50% of its public float, marking a slight decrease from the previous report. The short interest ratio is 28", "url": "https://www.marketbeat.com/stocks/NASDAQ/DMAC/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-25T10:41:14", "published_display": "25 Jun 2026 10:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts\u2019 Top Healthcare Picks: Diamedica Therapeutics (DMAC), Guardian Pharmacy Services, Inc. Class A (GRDN)", "summary": "This article highlights bullish analyst ratings for three healthcare companies: Diamedica Therapeutics (DMAC), Guardian Pharmacy Services, Inc. Class A (GRDN), and Eledon Pharmaceuticals (ELDN). Analysts from Lake Street, Bank of America Securities, and Noble Financial reiterate ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/DMAC/pressreleases/2626872/analysts-top-healthcare-picks-diamedica-therapeutics-dmac-guardian-pharmacy-services-inc-class-a-grdn/", "source_name": "The Globe and Mail", "published_at": "2026-06-25T04:11:36", "published_display": "25 Jun 2026 04:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction", "summary": "DiaMedica Therapeutics has initiated a Phase 2 trial for DM199 (rinvecalinase alfa) to treat fetal growth restriction (FGR), a severe pregnancy complication often leading to stillbirth. The trial will evaluate DM199's safety and efficacy in up to 30 patients with early-onset FGR,", "url": "https://finance.yahoo.com/healthcare/articles/diamedica-therapeutics-announces-first-patients-123000655.html", "source_name": "Market source", "published_at": "2026-06-25T02:39:32", "published_display": "25 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Up 10%, Insider Buyers Are Up 43%", "summary": "DiaMedica Therapeutics (NASDAQ:DMAC) saw its shares increase by 10% last week, rewarding insiders who had purchased stock in the past year with a 43% gain on their initial investment. The largest insider purchase was made by Thomas von Koch for US$10.0m at US$3.50 per share, sign", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmac/diamedica-therapeutics/news/diamedica-therapeutics-up-10-insider-buyers-are-up-43/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-24T14:12:43", "published_display": "24 Jun 2026 14:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Doses First Patients in Phase 2 Fetal Growth Restriction Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/diamedica-therapeutics-doses-first-patients-132614887.html", "source_name": "MT Newswires", "published_at": "2026-06-23T13:26:14+00:00", "published_display": "23 Jun 2026 13:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica doses first patients in fetal growth restriction trial", "summary": "DiaMedica Therapeutics Inc. has begun dosing patients in a Phase 2 trial for DM199 (rinvecalinase alfa) to treat fetal growth restriction, a condition affecting about 10% of pregnancies with no approved pharmacologic therapies. The trial aims to assess safety and tolerability in ", "url": "https://www.investing.com/news/company-news/diamedica-doses-first-patients-in-fetal-growth-restriction-trial-93CH-4755586", "source_name": "Investing.com", "published_at": "2026-06-23T13:41:33", "published_display": "23 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica starts first clinical test of DM199 in fetal growth restriction", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPODhMTDhfQktKc3dCNkgwbjRrUWlpaWJfME1NN1ktRTF2OUFyekxybGdtVVdLTUU0dldlWW9PTWRnTjZid2wxcENjb09CQUhublh4cDNOS09tZVBON1VKWF9KU2xtWV81SDViUkh5RC1jbllxSHM0Vm45SUdEMm5sQnRwRXczSGxBU0gyWFpkZDkxRjdSTDJFdUItR2ZwZWNqeFVQbVRXd0JDdjZ2US1VQVM2VFZmMllnYXBRZQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $14", "summary": "Lake Street has reiterated its Buy rating on DiaMedica Therapeutics (DMAC.US), maintaining a target price of $14. The affirmation of the rating and price target suggests continued confidence in the company's prospects by the analyst firm.", "url": "https://www.moomoo.com/news/post/71902137/lake-street-maintains-diamedica-therapeutics-dmacus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-22T01:11:05", "published_display": "22 Jun 2026 01:11", "sentiment": "positive", "sentiment_pct": 92, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Inc (DMAC) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of DiaMedica Therapeutics Inc (DMAC)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and reports \"No Data\" for both dividend payments and stock splits, indicating a lack o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmac/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T19:40:56", "published_display": "18 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating", "summary": "Craig-Hallum has reiterated its Buy rating for DiaMedica Therapeutics (DMAC.US). This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71726807/craig-hallum-maintains-diamedica-therapeutics-dmacus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-18T19:11:28", "published_display": "18 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Inc (DMAC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for DiaMedica Therapeutics Inc (DMAC), ranking its current earnings forecast score at 8.00 within the Biotechnology & Medical Research industry. Analysts have set an average price target of $13.00 for DMAC, with a consensus \"Buy\" rating b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmac/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:39:24", "published_display": "18 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Inc", "summary": "This article provides an overview of DiaMedica Therapeutics Inc (DMAC), including its current stock price and market capitalization. It indicates that relevant detailed revenue breakdown data by business segment and region has not yet been disclosed by the company. The page serve", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmac/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:24", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Receives US FDA Guidance on DM199 Nonclinical Requirements", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/diamedica-therapeutics-receives-us-fda-130536710.html", "source_name": "MT Newswires", "published_at": "2026-06-16T13:05:36+00:00", "published_display": "16 Jun 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica to conduct rat study addressing FDA data request", "summary": "DiaMedica Therapeutics Inc. will conduct a rat study to address an FDA request for additional nonclinical reproductive toxicity data for DM199, a treatment for preeclampsia. The company needs to demonstrate sufficient DM199 exposure and enzymatic activity in rats to support their", "url": "https://www.investing.com/news/company-news/diamedica-to-conduct-rat-study-addressing-fda-data-request-93CH-4744862", "source_name": "Investing.com", "published_at": "2026-06-16T13:40:17", "published_display": "16 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program", "summary": "DiaMedica Therapeutics Inc. announced it received FDA feedback on its DM199 preeclampsia nonclinical program, requiring additional reproductive toxicity data. The company plans to conduct a rat pharmacokinetic and activity study to address the FDA's request and support a U.S. inv", "url": "https://www.businesswire.com/news/home/20260616162333/en/DiaMedica-Receives-FDA-Feedback-on-DM199-Preeclampsia-Nonclinical-Program", "source_name": "Business Wire", "published_at": "2026-06-16T12:40:16", "published_display": "16 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA asks for more data on DiaMedica\u2019s preeclampsia drug, rat study planned", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOcFk2Q1dzSEJRTlg3ZVpZX0ozLXJ0RTUxcXlpRWFBS2FvRGp5cmczQ2lISUpGMUZSX2pyTzVwS1lYcW5kX0pXbEQxUEZHaUlDd1p1MHFVRGZuQXBqTDZ4MzdWZXBUR0g3emtscDhFd3Z6LWpIdVJobWpXMkFEOVRIYmcxcGhwYUVVbXRNdnlhVk5iVGVhbFV5aEhReGI3VHd0Y29YSkpOQm5TX19fQnYzbzJJeFgwa2VQTXByc0tn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica to conduct rat study addressing FDA data request By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxONWlDbFl3UzI4QjNNX2ZOdVFzVUVKMkRrMnh6OGF6VU9RR0wweXJWbzA2eHZxUFhyckVaRWtaZGVHZDl1MVpUY3NnbEd4cGFOMFdWRmpEYjNwQTRYUEVrUS14SnEtTXNIRmFCeHpnZFE1bzdVQ3cxcVNvMXdDRVg4UG5lWERZeHBEbEJydlMzYlFBbTFCS0J3cC1UVHJTX2I0RVRhVnZtUkxoTXhQUGx4djBKMTNtSkRmdnZZ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stroke and preeclampsia biotech DiaMedica joins New York healthcare conference", "summary": "DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focusing on treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, announced its presentation at the 2026 Jefferies Global Healthcare Conference in New York. The comp", "url": "https://www.stocktitan.net/news/DMAC/dia-medica-therapeutics-to-present-at-the-jefferies-global-4xolyr0wt3gk.html", "source_name": "Stock Titan", "published_at": "2026-06-13T03:39:26", "published_display": "13 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) director receives 40,412-share stock option grant", "summary": "DiaMedica Therapeutics Inc. director Charles Pauling Semba was granted options for 40,412 shares of Voting Common Shares at an exercise price of $5.84 per share, expiring on June 1, 2036. These options are scheduled to vest in four equal quarterly installments. This grant is cons", "url": "https://www.stocktitan.net/sec-filings/DMAC/form-4-dia-medica-therapeutics-inc-insider-trading-activity-2c8a802952e0.html", "source_name": "Stock Titan", "published_at": "2026-06-04T01:10:05", "published_display": "04 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica (DMAC) director Richard Kuntz receives grant of 40,412 stock options", "summary": "DiaMedica Therapeutics Inc. director Richard Kuntz was granted 40,412 stock options with an exercise price of $5.84 per share, expiring on June 1, 2036. These options vest in four equal quarterly installments. Following this transaction, Kuntz directly holds 40,412 derivative sec", "url": "https://www.stocktitan.net/sec-filings/DMAC/form-4-dia-medica-therapeutics-inc-insider-trading-activity-409d1c791888.html", "source_name": "Stock Titan", "published_at": "2026-06-04T00:10:47", "published_display": "04 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) CEO awarded 380,000 stock options", "summary": "DiaMedica Therapeutics (DMAC) CEO Dietrich John Pauls was granted 380,000 stock options as compensation, not an open-market trade. The options have an exercise price of $5.84 per share and expire on June 1, 2036. These options will vest 25% on the one-year anniversary of the gran", "url": "https://www.stocktitan.net/sec-filings/DMAC/form-4-dia-medica-therapeutics-inc-insider-trading-activity-57357fa7dd17.html", "source_name": "Stock Titan", "published_at": "2026-06-03T23:40:54", "published_display": "03 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) CFO awarded 162,000 stock options at $5.84 strike", "summary": "DiaMedica Therapeutics Inc. CFO and Secretary, Kellen Scott, was granted 162,000 stock options with an exercise price of $5.84 per share. These options, part of compensation rather than a market purchase, will vest 25% after one year and the remainder in twelve quarterly installm", "url": "https://www.stocktitan.net/sec-filings/DMAC/form-4-dia-medica-therapeutics-inc-insider-trading-activity-d1d9d6ceb299.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:39:15", "published_display": "03 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) director granted 40,412 stock options at $5.84", "summary": "DiaMedica Therapeutics (DMAC) director Randall Michael Giuffre was granted 40,412 stock options at an exercise price of $5.84 per share. These options are for Voting Common Shares, expire on June 1, 2036, and will vest in four equal quarterly installments. This transaction was re", "url": "https://www.stocktitan.net/sec-filings/DMAC/form-4-dia-medica-therapeutics-inc-insider-trading-activity-5957ec42bc39.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:39:14", "published_display": "03 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) director granted 40,412-share stock option award", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQS3NzRHpXa1I4V1kxOVpZVXAxaFV0Uk9vdzYtMXFLWXhFRmlhUUI2aGZxZERvY25DazdkdFlOcHNXQVo2TXk0ZnkzdkFRVWp5ckpVWlBJNE5xOThCOEFnazVQZ3BoZ2VtNXFjRDc3ck9lRjZ0YkJ3azZRQUtnX2llUGxMLTYzbV9BTFpndEE2cjhMTEs1NDg4elFPSFRFeThmZWtIakc1Q2VJU0Z6VnBOM2hzSE1HWXVpTmFiTEVB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica (DMAC) Q4 2025 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/378f9db6-afab-35e7-9e0f-880bb1213830/diamedica-%28dmac%29-q4-2025.html", "source_name": "Motley Fool", "published_at": "2026-06-01T20:17:45+00:00", "published_display": "01 Jun 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOWU10MXVlT0hFRXpPOXlTcVFxX0ladXY5ZGNZVEZfT0NPazM4WW9LX0dSSjU4RU9OZzVMQWk3cEV2c0FmNzVRel9RQkZQVmZpX0dlRm9idGJ6N2VFWnZOdjhzanVIMExOcTVnWDN1aGZSOXl2WU9NUmE2UlJuWkpZejI4TTd6UkY1M0tXTy1qTlJLWDFaQWRHb1I1S0JMeGtBVTRQdHZkeXZvRGhsQUtvNnVVbThkVEZ5RDQzQXpZY1psMGU3Wk9RVFoxeV8tT3RhRlh4RHNHLUg?oc=5", "source_name": "Business Wire", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/diamedica-therapeutics-says-trial-dm199-130510065.html", "source_name": "MT Newswires", "published_at": "2026-05-20T13:05:10+00:00", "published_display": "20 May 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stroke drug trial nears key review as DiaMedica reaches 75% enrollment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPNzVscVFid29wYXIzSkswMnFiNU85Q0JnV05vd0ZwS2lvRlI5Y01kbi15aVhqLTJOb19BRXQySWJMelIwOGhYY0xyY2plbm9NX19XWU9zeEgzQkQ5bUlZSGpZX1ZBbEJqYjVrcmZKMTdyTTBBQ29pMjdqWWxqN3R3cE94TTZmeWhweG1tS0I3eVBwZkg1SGhZR1Y3d3dVUVl5cjdCYmpaZko3ZTQ1ZzNsRFdqdkpBU3ZSRmt3OU5B?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQdjMyZGJmNTl4emdtaDJPQVY0el9aU210R2VaV290clZtMHpxdUswazdKMmstelRYMmtXdGRkaERabFJUR3lReFFoajh5ekRIcXdyRTdkYzc2dnFxb1ZmdEt5YnlIaXlEeDZ0ekdScjg1M3VFbTdqSktZcnJhMGtGRTcxVTV5dzFWU1QtNjgzTjNMRzg4SVFWa1BWVHU3Z1QyNnJsaVJuNA?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica (DMAC) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/af45708b-2464-30fd-8ea5-f80e04e10170/diamedica-%28dmac%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-08T15:25:22+00:00", "published_display": "08 May 2026 15:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/4245b946-890e-36ea-9a3d-1bc78a0dd534/diamedica-therapeutics-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-07T17:42:43+00:00", "published_display": "07 May 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNd2dpVnVkb0hsdFphR2dZZTktbVk0NldxeHZ2eUhmMFpmVnNkMkluOWFraXdjUVpxN3draUE3cHh1WnhraWZhc2FBT21XYkJNaEdFMWRYUklhSzhaX0pqUEJUN1VoSThKUkFrLVNTZ2U4cV8ydnZWalNCaTczWDRWQjZxXzA1a1k4MGt6REU1bmREck9pUjRxajFscDcxMmh1cDFMcTBsaHhsRXM5c0ZKUDd1TlMxc3EyNzByeEdoWWs3LUQ2YmtsVFZiMXlYZE9JLWRzcGFZaw?oc=5", "source_name": "BioSpace", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Insiders continue to buy DiaMedica Therapeutics Inc. (NASDAQ:DMAC) and now own 47% shares", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE9FZFVmX3BaNXJIZGVkU0pUa3JvWS1RbF9iYnozbWI0YURVYXh5VW52TjlnLWprTENGWFNrdTdka29ZVkNZdk5SSkVPTHVoVmVNQWlKNnR3Nm5ZWTFoV212N2xtMk1nRXBW?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-10T03:10:04+00:00", "published_display": "10 Jul 2025 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBYTm5yNmowSjFXRXExUDlnc0dxdE52SVJJdk9TQzR2c0JuTk5BTG15V0pjenVSVmZyZGNWTHdCemtrelpTblVXNWtFVmt4VENZVWF5dm9UMTc5QQ?oc=5", "source_name": "MarketBeat", "published_at": "2018-12-10T20:16:43+00:00", "published_display": "10 Dec 2018 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/diamedica-announces-inducement-grants-under-203000631.html", "source_name": "Business Wire", "published_at": "2026-07-17T20:30:00+00:00", "published_display": "17 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New DiaMedica hire gets 160,000 stock options at $7.64", "summary": "DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it granted options to a newly hired non-executive employee to purchase 160,000 shares of common stock. The stock options, with an exercise price of $7.64 per share, were a material inducement for their employment, complyin", "url": "https://www.stocktitan.net/news/DMAC/dia-medica-announces-inducement-grants-under-nasdaq-listing-rule-atn7kk24o63i.html", "source_name": "Stock Titan", "published_at": "2026-07-17T20:10:45", "published_display": "17 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(DMAC) Risk Channels and Responsive Allocation", "summary": "Diamedica Therapeutics Inc. (NASDAQ: DMAC) is showing conflicting sentiment across horizons, suggesting choppy conditions. The article highlights an exceptional 79.0:1 risk-reward setup targeting a 21.9% gain versus 0.3% risk. AI models have generated three distinct trading strat", "url": "https://news.stocktradersdaily.com/news_release/10/DMAC_Risk_Channels_and_Responsive_Allocation_071526072801_1784114881.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T07:12:23", "published_display": "15 Jul 2026 07:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) Short Interest & Short Float | Updated Jul 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE02NUdaa2lVbm5ncWFKQnZlLUFfSXpCdkI4M3JCZWZ0TjVjdDYwMUtFQnR3bVZwNmlPNHVEM05Qa1JJbXRCaVNpczZFWFN0U0tpX3MwV2o5cmdncjBnNHUxbEhFdU9lSEd0OC1tRDZB?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of DiaMedica Therapeutics Inc. \u2013 NASDAQ:DMAC", "summary": "The article discusses the enterprise value to revenue forward for DiaMedica Therapeutics Inc. (NASDAQ: DMAC). It highlights financial data available on TradingView, covering various aspects of the company's financial performance.", "url": "https://www.tradingview.com/symbols/NASDAQ-DMAC/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T16:12:23", "published_display": "08 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMAC PE Ratio & Valuation, Is DMAC Overvalued", "summary": "DiaMedica Therapeutics Inc (DMAC) is currently in the \"Fair zone\" according to its forward PS ratio, which is 0.00 compared to a five-year average of -4.69. The company's current Price-to-Book (P/B) ratio of 9.14 is significantly higher than its 3-year and 5-year averages, and it", "url": "https://intellectia.ai/en/stock/DMAC/valuation", "source_name": "Intellectia AI", "published_at": "2026-07-08T02:39:32", "published_display": "08 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of DiaMedica Therapeutics Inc. \u2013 NASDAQ:DMAC", "summary": "This article provides the enterprise value to EBITDA forward for DiaMedica Therapeutics Inc. (NASDAQ:DMAC). It presents financial data and company overview information sourced from TradingView, FactSet, and other financial data providers.", "url": "https://www.tradingview.com/symbols/NASDAQ-DMAC/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T03:47:28", "published_display": "07 Jul 2026 03:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics | 10-Q: Q1 2026 Earnings Report", "summary": "This document is the official 10-Q filing for DiaMedica Therapeutics, detailing their earnings report for the first quarter of 2026. As a regulatory filing, it provides a comprehensive overview of the company's financial performance and operational activities during that period.", "url": "https://www.moomoo.com/news/notice/307236683/diamedica-therapeutics-10-q-q1-2026-earnings-report", "source_name": "Moomoo", "published_at": "2026-07-07T03:39:26", "published_display": "07 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of DiaMedica Therapeutics Inc. \u2013 NASDAQ:DMAC", "summary": "This article section displays the \"Price to sales forward\" metric for DiaMedica Therapeutics Inc. (NASDAQ: DMAC). It indicates that the market was closed at the time of viewing and no trades were recorded for this specific financial data point.", "url": "https://www.tradingview.com/symbols/NASDAQ-DMAC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T22:40:31", "published_display": "06 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Inc. Actuals & Estimates (NASDAQ:DMAC)", "summary": "This article provides an overview of DiaMedica Therapeutics Inc. (NASDAQ: DMAC) stock performance, financial estimates, and analyst forecasts. It details the current stock price, historical highs and lows, market capitalization, and upcoming earnings report. The piece also includ", "url": "https://www.tradingview.com/symbols/NASDAQ-DMAC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:46", "published_display": "26 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMAC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for DiaMedica Therapeutics Inc. (DMAC), detailing analyst opinions, historical price performance, and key financial metrics. It highlights that analysts have a max price estimate of $25.00 and a min estimate of $11.00 for DMAC, wit", "url": "https://www.tradingview.com/symbols/NASDAQ-DMAC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T21:09:16", "published_display": "25 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) Short Interest & Short Float | Updated Jun 2026", "summary": "This article provides an update on DiaMedica Therapeutics (DMAC) short interest and short float as of June 15, 2026. DMAC had 4.86 million shares sold short, representing 9.50% of its public float, marking a slight decrease from the previous report. The short interest ratio is 28", "url": "https://www.marketbeat.com/stocks/NASDAQ/DMAC/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-25T10:41:14", "published_display": "25 Jun 2026 10:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts\u2019 Top Healthcare Picks: Diamedica Therapeutics (DMAC), Guardian Pharmacy Services, Inc. Class A (GRDN)", "summary": "This article highlights bullish analyst ratings for three healthcare companies: Diamedica Therapeutics (DMAC), Guardian Pharmacy Services, Inc. Class A (GRDN), and Eledon Pharmaceuticals (ELDN). Analysts from Lake Street, Bank of America Securities, and Noble Financial reiterate ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/DMAC/pressreleases/2626872/analysts-top-healthcare-picks-diamedica-therapeutics-dmac-guardian-pharmacy-services-inc-class-a-grdn/", "source_name": "The Globe and Mail", "published_at": "2026-06-25T04:11:36", "published_display": "25 Jun 2026 04:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction", "summary": "DiaMedica Therapeutics has initiated a Phase 2 trial for DM199 (rinvecalinase alfa) to treat fetal growth restriction (FGR), a severe pregnancy complication often leading to stillbirth. The trial will evaluate DM199's safety and efficacy in up to 30 patients with early-onset FGR,", "url": "https://finance.yahoo.com/healthcare/articles/diamedica-therapeutics-announces-first-patients-123000655.html", "source_name": "Market source", "published_at": "2026-06-25T02:39:32", "published_display": "25 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Up 10%, Insider Buyers Are Up 43%", "summary": "DiaMedica Therapeutics (NASDAQ:DMAC) saw its shares increase by 10% last week, rewarding insiders who had purchased stock in the past year with a 43% gain on their initial investment. The largest insider purchase was made by Thomas von Koch for US$10.0m at US$3.50 per share, sign", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmac/diamedica-therapeutics/news/diamedica-therapeutics-up-10-insider-buyers-are-up-43/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-24T14:12:43", "published_display": "24 Jun 2026 14:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Doses First Patients in Phase 2 Fetal Growth Restriction Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/diamedica-therapeutics-doses-first-patients-132614887.html", "source_name": "MT Newswires", "published_at": "2026-06-23T13:26:14+00:00", "published_display": "23 Jun 2026 13:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica doses first patients in fetal growth restriction trial", "summary": "DiaMedica Therapeutics Inc. has begun dosing patients in a Phase 2 trial for DM199 (rinvecalinase alfa) to treat fetal growth restriction, a condition affecting about 10% of pregnancies with no approved pharmacologic therapies. The trial aims to assess safety and tolerability in ", "url": "https://www.investing.com/news/company-news/diamedica-doses-first-patients-in-fetal-growth-restriction-trial-93CH-4755586", "source_name": "Investing.com", "published_at": "2026-06-23T13:41:33", "published_display": "23 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica starts first clinical test of DM199 in fetal growth restriction", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPODhMTDhfQktKc3dCNkgwbjRrUWlpaWJfME1NN1ktRTF2OUFyekxybGdtVVdLTUU0dldlWW9PTWRnTjZid2wxcENjb09CQUhublh4cDNOS09tZVBON1VKWF9KU2xtWV81SDViUkh5RC1jbllxSHM0Vm45SUdEMm5sQnRwRXczSGxBU0gyWFpkZDkxRjdSTDJFdUItR2ZwZWNqeFVQbVRXd0JDdjZ2US1VQVM2VFZmMllnYXBRZQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $14", "summary": "Lake Street has reiterated its Buy rating on DiaMedica Therapeutics (DMAC.US), maintaining a target price of $14. The affirmation of the rating and price target suggests continued confidence in the company's prospects by the analyst firm.", "url": "https://www.moomoo.com/news/post/71902137/lake-street-maintains-diamedica-therapeutics-dmacus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-22T01:11:05", "published_display": "22 Jun 2026 01:11", "sentiment": "positive", "sentiment_pct": 92, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Inc (DMAC) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of DiaMedica Therapeutics Inc (DMAC)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and reports \"No Data\" for both dividend payments and stock splits, indicating a lack o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmac/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T19:40:56", "published_display": "18 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating", "summary": "Craig-Hallum has reiterated its Buy rating for DiaMedica Therapeutics (DMAC.US). This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71726807/craig-hallum-maintains-diamedica-therapeutics-dmacus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-18T19:11:28", "published_display": "18 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Inc (DMAC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for DiaMedica Therapeutics Inc (DMAC), ranking its current earnings forecast score at 8.00 within the Biotechnology & Medical Research industry. Analysts have set an average price target of $13.00 for DMAC, with a consensus \"Buy\" rating b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmac/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:39:24", "published_display": "18 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Inc", "summary": "This article provides an overview of DiaMedica Therapeutics Inc (DMAC), including its current stock price and market capitalization. It indicates that relevant detailed revenue breakdown data by business segment and region has not yet been disclosed by the company. The page serve", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmac/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:24", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Receives US FDA Guidance on DM199 Nonclinical Requirements", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/diamedica-therapeutics-receives-us-fda-130536710.html", "source_name": "MT Newswires", "published_at": "2026-06-16T13:05:36+00:00", "published_display": "16 Jun 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica to conduct rat study addressing FDA data request", "summary": "DiaMedica Therapeutics Inc. will conduct a rat study to address an FDA request for additional nonclinical reproductive toxicity data for DM199, a treatment for preeclampsia. The company needs to demonstrate sufficient DM199 exposure and enzymatic activity in rats to support their", "url": "https://www.investing.com/news/company-news/diamedica-to-conduct-rat-study-addressing-fda-data-request-93CH-4744862", "source_name": "Investing.com", "published_at": "2026-06-16T13:40:17", "published_display": "16 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program", "summary": "DiaMedica Therapeutics Inc. announced it received FDA feedback on its DM199 preeclampsia nonclinical program, requiring additional reproductive toxicity data. The company plans to conduct a rat pharmacokinetic and activity study to address the FDA's request and support a U.S. inv", "url": "https://www.businesswire.com/news/home/20260616162333/en/DiaMedica-Receives-FDA-Feedback-on-DM199-Preeclampsia-Nonclinical-Program", "source_name": "Business Wire", "published_at": "2026-06-16T12:40:16", "published_display": "16 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA asks for more data on DiaMedica\u2019s preeclampsia drug, rat study planned", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOcFk2Q1dzSEJRTlg3ZVpZX0ozLXJ0RTUxcXlpRWFBS2FvRGp5cmczQ2lISUpGMUZSX2pyTzVwS1lYcW5kX0pXbEQxUEZHaUlDd1p1MHFVRGZuQXBqTDZ4MzdWZXBUR0g3emtscDhFd3Z6LWpIdVJobWpXMkFEOVRIYmcxcGhwYUVVbXRNdnlhVk5iVGVhbFV5aEhReGI3VHd0Y29YSkpOQm5TX19fQnYzbzJJeFgwa2VQTXByc0tn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica to conduct rat study addressing FDA data request By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxONWlDbFl3UzI4QjNNX2ZOdVFzVUVKMkRrMnh6OGF6VU9RR0wweXJWbzA2eHZxUFhyckVaRWtaZGVHZDl1MVpUY3NnbEd4cGFOMFdWRmpEYjNwQTRYUEVrUS14SnEtTXNIRmFCeHpnZFE1bzdVQ3cxcVNvMXdDRVg4UG5lWERZeHBEbEJydlMzYlFBbTFCS0J3cC1UVHJTX2I0RVRhVnZtUkxoTXhQUGx4djBKMTNtSkRmdnZZ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stroke and preeclampsia biotech DiaMedica joins New York healthcare conference", "summary": "DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focusing on treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, announced its presentation at the 2026 Jefferies Global Healthcare Conference in New York. The comp", "url": "https://www.stocktitan.net/news/DMAC/dia-medica-therapeutics-to-present-at-the-jefferies-global-4xolyr0wt3gk.html", "source_name": "Stock Titan", "published_at": "2026-06-13T03:39:26", "published_display": "13 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) director receives 40,412-share stock option grant", "summary": "DiaMedica Therapeutics Inc. director Charles Pauling Semba was granted options for 40,412 shares of Voting Common Shares at an exercise price of $5.84 per share, expiring on June 1, 2036. These options are scheduled to vest in four equal quarterly installments. This grant is cons", "url": "https://www.stocktitan.net/sec-filings/DMAC/form-4-dia-medica-therapeutics-inc-insider-trading-activity-2c8a802952e0.html", "source_name": "Stock Titan", "published_at": "2026-06-04T01:10:05", "published_display": "04 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica (DMAC) director Richard Kuntz receives grant of 40,412 stock options", "summary": "DiaMedica Therapeutics Inc. director Richard Kuntz was granted 40,412 stock options with an exercise price of $5.84 per share, expiring on June 1, 2036. These options vest in four equal quarterly installments. Following this transaction, Kuntz directly holds 40,412 derivative sec", "url": "https://www.stocktitan.net/sec-filings/DMAC/form-4-dia-medica-therapeutics-inc-insider-trading-activity-409d1c791888.html", "source_name": "Stock Titan", "published_at": "2026-06-04T00:10:47", "published_display": "04 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) CEO awarded 380,000 stock options", "summary": "DiaMedica Therapeutics (DMAC) CEO Dietrich John Pauls was granted 380,000 stock options as compensation, not an open-market trade. The options have an exercise price of $5.84 per share and expire on June 1, 2036. These options will vest 25% on the one-year anniversary of the gran", "url": "https://www.stocktitan.net/sec-filings/DMAC/form-4-dia-medica-therapeutics-inc-insider-trading-activity-57357fa7dd17.html", "source_name": "Stock Titan", "published_at": "2026-06-03T23:40:54", "published_display": "03 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) CFO awarded 162,000 stock options at $5.84 strike", "summary": "DiaMedica Therapeutics Inc. CFO and Secretary, Kellen Scott, was granted 162,000 stock options with an exercise price of $5.84 per share. These options, part of compensation rather than a market purchase, will vest 25% after one year and the remainder in twelve quarterly installm", "url": "https://www.stocktitan.net/sec-filings/DMAC/form-4-dia-medica-therapeutics-inc-insider-trading-activity-d1d9d6ceb299.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:39:15", "published_display": "03 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) director granted 40,412 stock options at $5.84", "summary": "DiaMedica Therapeutics (DMAC) director Randall Michael Giuffre was granted 40,412 stock options at an exercise price of $5.84 per share. These options are for Voting Common Shares, expire on June 1, 2036, and will vest in four equal quarterly installments. This transaction was re", "url": "https://www.stocktitan.net/sec-filings/DMAC/form-4-dia-medica-therapeutics-inc-insider-trading-activity-5957ec42bc39.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:39:14", "published_display": "03 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) director granted 40,412-share stock option award", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQS3NzRHpXa1I4V1kxOVpZVXAxaFV0Uk9vdzYtMXFLWXhFRmlhUUI2aGZxZERvY25DazdkdFlOcHNXQVo2TXk0ZnkzdkFRVWp5ckpVWlBJNE5xOThCOEFnazVQZ3BoZ2VtNXFjRDc3ck9lRjZ0YkJ3azZRQUtnX2llUGxMLTYzbV9BTFpndEE2cjhMTEs1NDg4elFPSFRFeThmZWtIakc1Q2VJU0Z6VnBOM2hzSE1HWXVpTmFiTEVB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica (DMAC) Q4 2025 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/378f9db6-afab-35e7-9e0f-880bb1213830/diamedica-%28dmac%29-q4-2025.html", "source_name": "Motley Fool", "published_at": "2026-06-01T20:17:45+00:00", "published_display": "01 Jun 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOWU10MXVlT0hFRXpPOXlTcVFxX0ladXY5ZGNZVEZfT0NPazM4WW9LX0dSSjU4RU9OZzVMQWk3cEV2c0FmNzVRel9RQkZQVmZpX0dlRm9idGJ6N2VFWnZOdjhzanVIMExOcTVnWDN1aGZSOXl2WU9NUmE2UlJuWkpZejI4TTd6UkY1M0tXTy1qTlJLWDFaQWRHb1I1S0JMeGtBVTRQdHZkeXZvRGhsQUtvNnVVbThkVEZ5RDQzQXpZY1psMGU3Wk9RVFoxeV8tT3RhRlh4RHNHLUg?oc=5", "source_name": "Business Wire", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/diamedica-therapeutics-says-trial-dm199-130510065.html", "source_name": "MT Newswires", "published_at": "2026-05-20T13:05:10+00:00", "published_display": "20 May 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stroke drug trial nears key review as DiaMedica reaches 75% enrollment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPNzVscVFid29wYXIzSkswMnFiNU85Q0JnV05vd0ZwS2lvRlI5Y01kbi15aVhqLTJOb19BRXQySWJMelIwOGhYY0xyY2plbm9NX19XWU9zeEgzQkQ5bUlZSGpZX1ZBbEJqYjVrcmZKMTdyTTBBQ29pMjdqWWxqN3R3cE94TTZmeWhweG1tS0I3eVBwZkg1SGhZR1Y3d3dVUVl5cjdCYmpaZko3ZTQ1ZzNsRFdqdkpBU3ZSRmt3OU5B?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQdjMyZGJmNTl4emdtaDJPQVY0el9aU210R2VaV290clZtMHpxdUswazdKMmstelRYMmtXdGRkaERabFJUR3lReFFoajh5ekRIcXdyRTdkYzc2dnFxb1ZmdEt5YnlIaXlEeDZ0ekdScjg1M3VFbTdqSktZcnJhMGtGRTcxVTV5dzFWU1QtNjgzTjNMRzg4SVFWa1BWVHU3Z1QyNnJsaVJuNA?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica (DMAC) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/af45708b-2464-30fd-8ea5-f80e04e10170/diamedica-%28dmac%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-08T15:25:22+00:00", "published_display": "08 May 2026 15:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/4245b946-890e-36ea-9a3d-1bc78a0dd534/diamedica-therapeutics-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-07T17:42:43+00:00", "published_display": "07 May 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNd2dpVnVkb0hsdFphR2dZZTktbVk0NldxeHZ2eUhmMFpmVnNkMkluOWFraXdjUVpxN3draUE3cHh1WnhraWZhc2FBT21XYkJNaEdFMWRYUklhSzhaX0pqUEJUN1VoSThKUkFrLVNTZ2U4cV8ydnZWalNCaTczWDRWQjZxXzA1a1k4MGt6REU1bmREck9pUjRxajFscDcxMmh1cDFMcTBsaHhsRXM5c0ZKUDd1TlMxc3EyNzByeEdoWWs3LUQ2YmtsVFZiMXlYZE9JLWRzcGFZaw?oc=5", "source_name": "BioSpace", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders continue to buy DiaMedica Therapeutics Inc. (NASDAQ:DMAC) and now own 47% shares", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE9FZFVmX3BaNXJIZGVkU0pUa3JvWS1RbF9iYnozbWI0YURVYXh5VW52TjlnLWprTENGWFNrdTdka29ZVkNZdk5SSkVPTHVoVmVNQWlKNnR3Nm5ZWTFoV212N2xtMk1nRXBW?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-10T03:10:04+00:00", "published_display": "10 Jul 2025 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBYTm5yNmowSjFXRXExUDlnc0dxdE52SVJJdk9TQzR2c0JuTk5BTG15V0pjenVSVmZyZGNWTHdCemtrelpTblVXNWtFVmt4VENZVWF5dm9UMTc5QQ?oc=5", "source_name": "MarketBeat", "published_at": "2018-12-10T20:16:43+00:00", "published_display": "10 Dec 2018 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 54, "sentiment_summary": {"positive": 17, "negative": 2, "neutral": 35, "score": 56, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 17.05, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 7.3, "latest_week": "2026-07-17", "one_week_move": -4.8, "four_week_move": 24.8, "twelve_week_move": 15.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.996253, "market_dynamics_buy_signal": false, "relative_strength": -5.537222, "fair_value_gap": 53.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 58.1548, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.8% over one week, +24.8% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 8}, {"label": "MarketBeat", "count": 5}, {"label": "TradingView", "count": 5}, {"label": "Business Wire", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "TradingKey", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.8% over one week, +24.8% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}], "updated_at": "2026-07-18T19:13:52.498219+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}